Australia markets closed

Evoke Pharma, Inc. (EVOK)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.3220-0.0048 (-1.47%)
As of 09:37AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 8.06M
Enterprise value 3.93M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)4.87
Price/book (mrq)2.27
Enterprise value/revenue 2.43
Enterprise value/EBITDA -0.49

Trading information

Stock price history

Beta (5Y monthly) 0.75
52-week change 3-73.84%
S&P500 52-week change 3-0.65%
52-week high 31.5800
52-week low 30.2260
50-day moving average 30.4536
200-day moving average 30.7936

Share statistics

Avg vol (3-month) 34.89M
Avg vol (10-day) 32.58M
Shares outstanding 540.12M
Implied shares outstanding 6N/A
Float 831.93M
% held by insiders 12.46%
% held by institutions 15.28%
Shares short (28 Apr 2022) 41.77M
Short ratio (28 Apr 2022) 40.16
Short % of float (28 Apr 2022) 45.55%
Short % of shares outstanding (28 Apr 2022) 45.39%
Shares short (prior month 30 Mar 2022) 4141.2k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Dec 2021

Profitability

Profit margin 0.00%
Operating margin (ttm)-503.79%

Management effectiveness

Return on assets (ttm)-50.93%
Return on equity (ttm)-5,015.39%

Income statement

Revenue (ttm)1.62M
Revenue per share (ttm)0.05
Quarterly revenue growth (yoy)1,466.30%
Gross profit (ttm)1.29M
EBITDA N/A
Net income avi to common (ttm)-8.54M
Diluted EPS (ttm)-0.2650
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)9.14M
Total cash per share (mrq)0.28
Total debt (mrq)5.01M
Total debt/equity (mrq)140.99
Current ratio (mrq)7.51
Book value per share (mrq)0.11

Cash flow statement

Operating cash flow (ttm)-12.35M
Levered free cash flow (ttm)-9.63M